Sun Pharmaceutical Industries Limited

BSE: 524715 NSE: SUNPHARMA
Sun Pharmaceutical Industries Limited - pharma in Vadodara, Gujarat, India. FY 2026 financials & compliance.
CIN L24230GJ1993PLC019050 Incorporated 01 March 1993 ROC Ahmedabad HQ Vadodara, Gujarat, India
Active Listed - NSE: SUNPHARMA · BSE: 524715 Public Limited Company pharma Fortune India 500 · #53 India's Most Valuable · #10 Nifty 50
Data last updated
Market Cap
₹4,19,404 Cr
SUNPHARMA · NSE
Share Price
₹1,740.00
-0.46% today
Revenue
₹58,462 Cr
FY 2025-26 · +11.2% YoY
EBITDA
₹15,184 Cr
Margin 26.0%
Net Profit
₹12,429 Cr
FY 2025-26 · +8.5% YoY
P/E (TTM)
33.2x
P/B 5.0x
ROE
14.8%
ROCE 18.7%
Debt / Equity
0.04
Interest cover 2.8x

About Sun Pharmaceutical Industries Limited

Data last updated:

Sun Pharmaceutical Industries Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 March 1993 and has been in existence for over 33 years.

Sun Pharmaceutical Industries is ranked #53 on the Fortune India 500 (2025) and #10 among India's most valuable companies (2025). It is part of the Nifty 50, Sensex, Nifty 500 and BSE 500 indices. Its director Dilip Shanghvi is #7 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1993PLC019050. Its GSTIN is 24AADCS3124K1ZJ (Gujarat). The company holds 41 GST registrations, of which 33 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524715 and NSE: SUNPHARMA.

The company has an authorised share capital of ₹617.97 Cr and a paid-up capital of ₹239.93 Cr. It is led by directors including Kirti Wardhaman Ganorkar (Managing Director) and Dilip Shantilal Shanghvi (Whole-Time Director).

Its last annual general meeting (AGM) was held on 31 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sparc Tandalja, Vadodara, Gujarat, India – 390012.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹58,462 Cr, a growth of 11.2% compared to the previous year. For the same year it recorded a net profit of ₹12,429 Cr (net margin 21.3%) and EBITDA of ₹15,184 Cr (EBITDA margin 26%). The net worth stands at ₹83,570 Cr (up 15.7% YoY). Total assets are valued at ₹90,020 Cr (up 18.9% YoY).

The company has about 16,436 employees on its provident fund (EPFO) records. Its group structure includes 14 subsidiaries.

The company is associated with 2 brands: Flore and Sun Pharma. As per MCA filings, the company has open charges of ₹16.06 Cr and satisfied charges of ₹1,785.22 Cr on record. Court records list 956 cases involving the company, including 668 filed by the company and 289 filed against it; 349 cases are pending. The company has 75 deals on record (61 market trades, 6 acquisitions, 4 funding rounds), with disclosed funding of ₹1,610.24 Cr; the latest was in June 2026. Its 5 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 smaller; the largest is Dr.Reddy's Laboratories Ltd with revenue of ₹33,741 Cr. The company has 313 MSME Form 1 returns on record between 2007 and 2024, listing 25,487 overdue payments to 1,670 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sunpharma.com.

Company details

CIN L24230GJ1993PLC019050
Registration Number 019050
Incorporation Date 01 March 1993
ROC Ahmedabad
Listing Status Listed - Listed on NSE (SUNPHARMA); Listed on BSE (524715)
Company Status Active
Date of Last AGM 31 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Kirti Wardhaman Ganorkar Managing Director Dilip Shantilal Shanghvi Whole-Time Director Vidhi Dilip Shanghvi Whole-Time Director

Recognitions & Rankings of Sun Pharmaceutical Industries

Fortune India 500 2025 edition
Rank#53
Total income
₹54,579 Cr
Profit
₹10,929 Cr
Last year #54
India's Most Valuable Companies 2025 edition · Source: Hurun India
Rank#10
Valuation
₹4,33,880 Cr
1-year change
0%
2024 #11 2023 #14 2022 #21
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 50 Sensex Nifty 500 BSE 500

Contact details

Sun Pharmaceutical Industries Limited's registered office is in Vadodara, Gujarat. Its website is sunpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    sunpharma.com
  • Social Media
  • Registered Address
    Sparc Tandalja, Vadodara, Gujarat, India – 390012
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers

To see the full contact details of Sun Pharmaceutical Industries Limited, buy the company report.

Comprehensive company report
Sun Pharmaceutical Industries Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Sun Pharmaceutical Industries operates two associated brands: Flore and Sun Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Flore
Customized probiotics for gut health are provided via stool analysis.flore.com
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.sunpharma.com

Business activity

The main business activity of Sun Pharmaceutical Industries is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Sun Pharmaceutical Industries Limited, buy the company report.

Financials of Sun Pharmaceutical Industries Limited

FY 2025-26 filings available

Sun Pharmaceutical Industries Limited reported revenue of ₹58,462 Cr (up 11.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹58,462 Cr
+11.2% YoY
EBITDA
₹15,184 Cr
+5.4% YoY
Profit After Tax
₹12,429 Cr
+8.5% YoY
Net Worth
₹83,570 Cr
+15.7% YoY
Total Assets
₹90,020 Cr
+18.9% YoY
Total Debt
₹4,627 Cr
+95.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue58,46252,57848,49743,88638,65433,49832,838
Revenue growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
EBITDA15,18414,40812,49311,4755,6774,1626,714
EBITDA margin+26.0%+27.4%+25.8%+26.2%+14.7%+12.4%+20.4%
Profit before tax15,11913,75211,0889,4084,4812,7995,010
Net profit12,42911,4569,9908,6056,7175,7283,961
Net profit margin+21.3%+21.8%+20.6%+19.6%+17.4%+17.1%+12.1%
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
Balance sheet
Total assets90,02075,71871,31467,13153,37654,44758,774
Net worth83,57072,21863,66755,99548,01146,46345,264
Total debt4,6272,3623,2746,8861,2903,8698,315
Cash & bank11,60311,33210,5215,7705,0336,4466,488
Net working capital24,53922,74820,83516,90910,83114,13717,336
Cash flow
Cash from operations12,41914,07212,1354,9598,9856,1706,555
Cash from investing(10,405)(5,183)(763)(7,220)(5,556)407(2,225)
Cash from financing(2,513)(7,906)(6,710)2,376(5,193)(5,980)(5,715)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue15,30014,61215,52114,47813,85112,95913,67513,291
Revenue growth (YoY)+10.5%+12.8%+13.5%+8.9%+9.5%---
Other income724458579470464613466354
EBITDA4,2143,9544,4594,5273,4843,3543,6933,939
EBITDA margin+27.8%+27.2%+28.8%+31.4%+25.3%+26.2%+27.5%+29.7%
Depreciation739775732730701664631626
Interest99.6785.8978.3699.8674.8049.1451.5169.17
Profit before tax4,0993,5514,2274,1683,1733,2543,4763,598
Tax1,1888288261,0318701,094559567
Net profit2,9112,7243,4013,1372,3032,1612,9183,031
EPS (₹)12.1011.3014.0013.009.509.0012.1012.70
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,75522,97720,27520,81215,58614,11612,532
Revenue growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
EBITDA4,2776,5835,2813,4858482,1672,712
EBITDA margin+20.6%+28.7%+26.1%+16.7%+5.4%+15.4%+21.6%
Profit before tax3,7944,9763,4501,7413078563,253
Net profit2,9454,2183,0523,356(1,338)9063,018
Net profit margin+14.2%+18.4%+15.1%+16.1%-8.6%+6.4%+24.1%
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
Balance sheet
Total assets36,57636,64736,64432,64530,67835,63932,356
Net worth22,37123,90023,69423,74824,58826,93824,396
Total debt13,60511,94711,2277,7915,0747,3586,406
Cash & bank437911338421535361655
Net working capital10,19511,54910,4927,901(576)4,6035,492
Cash flow
Cash from operations6,5014,252(292)5077,636(417)1,306
Cash from investing(1,345)(251)(265)(686)(2,697)1,4521,483
Cash from financing(5,230)(3,836)474169(4,871)(1,000)(2,871)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,7414,9245,6884,5485,5957,1796,1815,122
Revenue growth (YoY)+2.6%-31.4%-8.0%-11.2%+24.4%---
Other income14062.9318072.7910413269.0595.21
Total expenses3,8083,5954,1883,3653,9734,1204,4763,791
EBITDA1,9331,3291,5001,1841,6223,0591,7051,332
EBITDA margin+34.3%+27.2%+26.5%+26.2%+29.2%+43.1%+28.5%+26.0%
Depreciation308326339336311305303297
Interest278217244248238232231259
Profit before tax1,4868491,0976721,1762,6541,240871
Tax37124039210843161283.8132.44

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue15,30014,61215,52114,47813,85112,95913,67513,291
Revenue growth (YoY)+10.5%+12.8%+13.5%+8.9%+9.5%---
Other income724458579470464613466354
EBITDA4,2143,9544,4594,5273,4843,3543,6933,939
EBITDA margin+27.8%+27.2%+28.8%+31.4%+25.3%+26.2%+27.5%+29.7%
Depreciation739775732730701664631626
Interest99.6785.8978.3699.8674.8049.1451.5169.17
Profit before tax4,0993,5514,2274,1683,1733,2543,4763,598
Tax1,1888288261,0318701,094559567
Net profit2,9112,7243,4013,1372,3032,1612,9183,031
EPS (₹)12.1011.3014.0013.009.509.0012.1012.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue58,46252,57848,49743,88638,65433,49832,838
Revenue growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
Other income3,2122,1511,3906351,075859652
Total expenses43,27838,17036,00432,41032,97829,33726,124
Employee cost11,4199,9739,4298,2967,3016,8626,362
EBITDA15,18414,40812,49311,4755,6774,1626,714
EBITDA margin+26.0%+27.4%+25.8%+26.2%+14.7%+12.4%+20.4%
Depreciation2,9382,5752,5572,5292,1442,0802,053
Interest339231238172127141303
Profit before tax15,11913,75211,0889,4084,4812,7995,010
Tax3,5542,7721,4398481,076515823
Net profit12,42911,4569,9908,6056,7175,7283,961
Net profit margin+21.3%+21.8%+20.6%+19.6%+17.4%+17.1%+12.1%
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital240240240240240240240
Reserves & surplus83,33071,97863,42755,75547,77146,22345,025
Shareholders' funds (net worth)83,57072,21863,66755,99548,01146,46345,264
Minority interest3102683,4593,3203,0553,0173,860
Secured loans0.000.000.000.000.007.83257
Unsecured loans4,6272,3623,2746,8861,2903,8618,057
Total debt4,6272,3623,2746,8861,2903,8698,315
Total liabilities90,02075,71871,31467,13153,37654,44758,774
Assets
Gross block60,32145,95044,32043,10038,70735,57935,116
Net block32,82222,58623,24824,06522,66521,55322,847
Capital work in progress3,0526,6445,3544,9731,2871,5671,220
Investments24,72318,35415,02614,82412,8499,61210,143
Inventories11,49310,2439,86810,5138,9258,9977,875
Sundry debtors15,51013,04611,24911,43910,4859,0619,421
Cash & bank balances11,60311,33210,5215,7705,0336,4466,488
Loans & advances4,3214,3173,2102,7672,7882,8082,973
Total current assets42,92738,93834,84930,48927,23127,31226,757
Total current liabilities18,38816,19014,01413,58016,40013,1759,420
Net working capital24,53922,74820,83516,90910,83114,13717,336
Total assets90,02075,71871,31467,13153,37654,44758,774
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10,2699,2864,6244,5086,2735,6777,062
Net cash from operating activities12,41914,07212,1354,9598,9856,1706,555
Net cash from investing activities(10,405)(5,183)(763)(7,220)(5,556)407(2,225)
Net cash from financing activities(2,513)(7,906)(6,710)2,376(5,193)(5,980)(5,715)
Net change in cash(498)9834,662115(1,765)596(1,386)
Closing cash11,60311,33210,5215,7705,0336,4466,488
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
EBITDA growth+5.4%+15.3%+8.9%+102.1%+36.4%-38.0%-
PBT growth+9.9%+24.0%+17.9%+110.0%+60.1%-44.1%+31.5%
Net income growth+8.5%+14.7%+16.1%+28.1%+17.3%+44.6%-
Revenue CAGR (3Y)+10.0%+10.8%+13.1%+10.2%+10.0%+8.1%+1.3%
EBITDA CAGR (3Y)+9.8%+36.4%+44.3%+19.6%+3.7%-3.7%-12.7%
Profitability & leverage
Net income margin+19.8%+20.9%+19.9%+19.5%+8.8%+6.8%+12.8%
Return on capital employed+18.7%+19.5%+17.2%+16.8%+18.0%+13.6%+9.9%
Return on net worth+14.9%+16.2%+16.1%+16.5%+14.5%+11.1%+9.7%
Debt / equity0.040.040.080.080.050.130.22
Long-term debt / equity0.000.000.010.010.010.030.04
Interest cover2.771.962.401.923.606.796.50
Efficiency & per share
Fixed asset turnover1.101.161.111.071.040.950.98
Inventory turnover5.385.234.764.524.313.974.17
Debtors turnover4.094.334.284.003.963.623.59
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
Dividend per share (₹)16.0016.0013.5011.5010.007.504.00
Book value per share (₹)348.31301.00265.36233.38200.11193.65188.66
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,7414,9245,6884,5485,5957,1796,1815,122
Revenue growth (YoY)+2.6%-31.4%-8.0%-11.2%+24.4%---
Other income14062.9318072.7910413269.0595.21
Total expenses3,8083,5954,1883,3653,9734,1204,4763,791
EBITDA1,9331,3291,5001,1841,6223,0591,7051,332
EBITDA margin+34.3%+27.2%+26.5%+26.2%+29.2%+43.1%+28.5%+26.0%
Depreciation308326339336311305303297
Interest278217244248238232231259
Profit before tax1,4868491,0976721,1762,6541,240871
Tax37124039210843161283.8132.44
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,75522,97720,27520,81215,58614,11612,532
Revenue growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
Other income1,7766345533291,1971921,511
Total expenses16,47716,39514,99417,32714,73811,9499,820
Employee cost2,9112,6912,3742,1572,0011,8061,703
EBITDA4,2776,5835,2813,4858482,1672,712
EBITDA margin+20.6%+28.7%+26.1%+16.7%+5.4%+15.4%+21.6%
Depreciation1,3121,2871,6011,6011,3501,236562
Interest948954784472388268408
Profit before tax3,7944,9763,4501,7413078563,253
Tax1,17174859150.3340713.1741.86
Net profit2,9454,2183,0523,356(1,338)9063,018
Net profit margin+14.2%+18.4%+15.1%+16.1%-8.6%+6.4%+24.1%
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital240240240240240240240
Reserves & surplus22,13123,66023,45423,50824,34826,69924,156
Shareholders' funds (net worth)22,37123,90023,69423,74824,58826,93824,396
Secured loans0.000.000.000.000.005.416.18
Unsecured loans13,60511,94711,2277,7915,0747,3536,400
Total debt13,60511,94711,2277,7915,0747,3586,406
Total liabilities36,57636,64736,64432,64530,67835,63932,356
Assets
Gross block20,68119,20018,25217,74517,19515,8128,245
Net block7,6137,3727,7378,7129,7139,6695,229
Capital work in progress8991,0847668538291,090597
Investments12,95212,41012,43012,61315,54915,53717,362
Inventories4,3023,9343,4243,9893,4043,4232,634
Sundry debtors10,16611,7028,8347,1254,2456,5856,168
Cash & bank balances437911338421535361655
Loans & advances1,7732,2342,3164,7081,3272,3292,089
Total current assets16,67918,78114,91316,2439,51112,69911,546
Total current liabilities6,4847,2314,4218,34310,0878,0966,055
Net working capital10,19511,54910,4927,901(576)4,6035,492
Total assets36,57636,64736,64432,64530,67835,63932,356
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash493327410420351315303
Net cash from operating activities6,5014,252(292)5077,636(417)1,306
Net cash from investing activities(1,345)(251)(265)(686)(2,697)1,4521,483
Net cash from financing activities(5,230)(3,836)474169(4,871)(1,000)(2,871)
Net change in cash(74.73)165(83.82)(9.25)68.4736.23(82.26)
Closing cash437911338421535361655
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
EBITDA growth-35.0%+24.7%+51.5%+310.9%-60.9%-20.1%-
PBT growth-23.8%+44.3%+98.1%+467.4%-64.1%-73.7%+352.2%
Net income growth-30.2%+38.2%-9.1%+351.0%-247.6%-70.0%-
Revenue CAGR (3Y)-0.1%+13.8%+12.8%+18.4%+14.8%+16.3%+17.7%
EBITDA CAGR (3Y)+7.1%+98.0%+34.6%+8.7%+16.1%+327.4%+187.6%
Profitability & leverage
Net income margin+12.6%+18.4%+14.1%+8.1%-0.6%+6.0%+25.6%
Return on capital employed+14.5%+16.2%+12.2%+16.3%+7.5%+3.6%+11.9%
Return on net worth+12.7%+17.8%+12.1%+13.9%-5.2%+3.5%+13.6%
Debt / equity0.550.490.400.270.240.270.27
Long-term debt / equity0.310.260.400.270.200.130.06
Interest cover31.9618.0121.3125.06-77.3228.7318.98
Efficiency & per share
Fixed asset turnover1.041.231.131.190.941.171.60
Inventory turnover5.046.255.475.634.574.664.62
Debtors turnover1.902.242.543.662.882.212.24
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
Dividend per share (₹)16.0016.0013.5011.5010.007.504.00
Book value per share (₹)93.2499.6198.7698.98102.48112.28101.68

To see the full year-wise statements and ratios of Sun Pharmaceutical Industries Limited, buy the company report.

Board of directors of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries has 9 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Pawan Kumar Goenka
Also directs: PMG Advisory LLP
Director21 May 20215 Years 5 MonthsCurrent
Dilip Shantilal Shanghvi
Also directs: Sun Pharma Advanced Research Company Limited, Sun Petrochemicals Private Limited, Alfa Infraprop Private Limited and 3 more
Whole-Time Director01 Apr 200818 Years 6 MonthsCurrent
Gautam Bhailal Doshi
Also directs: Bhavna Doshi Associates LLP, Piramal Finance Limited, Sun Pharma Laboratories Limited and 4 more
Director25 May 20188 Years 5 MonthsCurrent
Kirti Wardhaman Ganorkar
Also directs: Sun Pharma Laboratories Limited, Sun Pharma Distributors Limited
Managing Director01 Sep 20251 Years 1 MonthsCurrent
Vidhi Dilip Shanghvi
Also directs: Sun Pharma Advanced Research Company Limited, Sun Petrochemicals Private Limited, Vivaldis Health and Foods Private Limited and 1 more
Whole-Time Director22 May 20251 Years 5 MonthsCurrent
Aalok Dilip Shanghvi
Also directs: Shikha Learning Labs Private Limited
Whole-Time Director01 Jun 20233 Years 4 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Peer comparison

Sun Pharmaceutical Industries Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Sun Pharmaceutical Industries Limitedthis company₹58,462 Cr (FY 2026)₹12,429 Cr21.3%11.2%16,436Vadodara, Gujarat, India
Dr.Reddy's Laboratories Ltd₹33,741 Cr (FY 2025)17.0%Hyderabad, Telangana, India
Aurobindo Pharma Ltd₹32,346 Cr (FY 2025)9.0%Hyderabad, Telangana, India
Cipla Limited₹28,409 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Zydus Lifesciences Limited₹23,511 Cr (FY 2025)19.0%Ahmedabad, Gujarat, India
Lupin Limited₹22,904 Cr (FY 2025)14.0%Mumbai, Maharashtra, India

To see the full peer comparison of Sun Pharmaceutical Industries Limited, buy the company report.

Auditor

Sun Pharmaceutical Industries Limited is audited by S R B C & CO LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
S R B C & CO LLPFY 2024324982E/E300003

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 54.50%, foreign institutional investors hold 14.50%, domestic institutional investors hold 22.20% and retail and other public shareholders hold 8.80%.

Promoters: 54.50%DII (Domestic Institutional): 22.20%FII (Foreign Institutional): 14.50%Retail & Others: 8.80%
Sep 2026
QUARTER
54.50% Promoters
22.20% DII (Domestic Institutional)
14.50% FII (Foreign Institutional)
8.80% Retail & Others
Promoter holding - history
Now 54.50% · Sep 2026High 54.50% · Dec 2025Low 54.50% · Dec 2025
53%53.8%54.5%55.3%56%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 54.50%Mar 2026: 54.50%Jun 2026: 54.50%Sep 2026: 54.50%54.50%54.50%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters54.50%54.50%54.50%54.50%
Public45.50%45.50%45.50%45.50%

Charges & borrowings

Open charges
₹16.06 Cr
Satisfied charges
₹1,785.22 Cr
Breakdown by lending institutions
Industrial Development Bank of India₹12.45 Cr
Risk Capital and Technology Finance Corporation Ltd₹1.50 Cr
Gujarat Industrial Investment Corporation Ltd.₹1.36 Cr
Nvfc Finance Private Ltd₹0.75 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
26 May 199990095637Nvfc Finance Private Ltd₹75 LakhOpen
29 Apr 199990095112Risk Capital and Technology Finance Corporation Ltd₹1.5 CrOpen
17 Nov 199890095083Industrial Development Bank of India₹3.25 CrOpen
13 Sep 199690094937Industrial Development Bank of India₹9.2 CrOpen
11 Oct 199390101445Gujarat Industrial Investment Corporation Ltd.₹1.36 CrOpen

To see the full charge records of Sun Pharmaceutical Industries Limited, buy the company report.

Total charge records: 38 View all charges

Deals & funding

Sun Pharmaceutical Industries Limited has 75 deals on record (61 market trades, 6 acquisitions, 4 funding rounds), with disclosed funding of ₹1,610.24 Cr; the latest was in June 2026.

Total deals
75
Market trades
61
Acquisitions
6
Funding rounds
4
Secondary share transfers
4
Disclosed funding
₹1,610.24 Cr

Deals on record (5 of 75)

WhenDealAmountParties
Mar 2019Market trade₹47.12 CrBuyer: Gujarat State Financial Services Ltd
Seller: Gujarat State Investment Limited
Jul 2016Acquisition₹40.88 CrBuyer: RPG Life Sciences Limited
Seller: Sun Pharmaceutical Industries Limited
Jun 2016AcquisitionUndisclosedBuyer: Frontida Biopharm Inc
Seller: Sun Pharmaceutical Industries Limited
Dec 2015AcquisitionUndisclosedBuyer: Nostrum Laboratories Inc.
Seller: Sun Pharmaceutical Industries Limited
Sep 2015Acquisition₹164.88 CrBuyer: Strides Pharma Science Limited
Seller: Sun Pharmaceutical Industries Limited

To see the full deal history of Sun Pharmaceutical Industries Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Sun Pharmaceutical Industries Limited was last rated by Icra on 31 Mar 2022.

Rating agencyRated onRating
Icra31 Mar 2022

To see the full credit ratings and regulatory alerts of Sun Pharmaceutical Industries Limited, buy the company report.

MSME payment delays

Sun Pharmaceutical Industries Limited has 313 MSME Form 1 returns on record between 2007 and 2024, listing 25,487 overdue payments to 1,670 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 1,670)

SupplierAmount dueDue sinceReported on
Fynehand Consultants LLP
Element Engineers and Consultants
Biofuels Junction Private Limited
an individual supplier
Silicon Products Pvt Associates

To see the full MSME payment records of Sun Pharmaceutical Industries Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Sun Pharmaceutical Industries has 14 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

14
Subsidiary companies
1
Associated companies
Key subsidiaries
Company NameCINShares held
Zenotech Laboratories LimitedL27100TG1989PLC010122
Caraco Pharmaceuticals Private LimitedU24100MH2012FTC225970
Vivaldis Health and Foods Private LimitedU24297PN2014PTC150393
Sun Pharma Laboratories LimitedU25200GJ1997PLC133846
Sun Pharmaceutical Medicare LimitedU36900GJ2017PLC095132
Neetnav Real Estate Private LimitedU45200MH2010PTC201611

To see the full group structure of Sun Pharmaceutical Industries Limited, buy the company report.

Employees & EPFO

Sun Pharmaceutical Industries Limited has a workforce of 16,436 employees on its EPFO records as of Oct 28, 2024, across 7 active EPFO establishments.

Employee count
16,436
Active EPFO establishments
7
Employee growth
-15.94%

GST

Sun Pharmaceutical Industries has 41 GST registrations: 33 active and 8 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
41
Active
33
Cancelled / inactive
8
GSTINStateStatusRegistered on
24AADCS3124K1ZJGujaratActive01 Jul 2017
24AADCS3124K2ZIGujaratActive08 Jul 2017
02AADCS3124K1ZPHimachal PradeshActive01 Jul 2017
03AADCS3124K2ZMPunjabActive01 Jul 2017

To see the full GST registrations and return filing status of Sun Pharmaceutical Industries Limited, buy the company report.

Recent activity

Sun Pharmaceutical Industries Limited has 42 board changes on record since 1994: 27 appointments and 15 cessations. The latest: Andreas Eugen Busch was appointed as Director on 12 May 2026.

AGM
Sun Pharmaceutical Industries Limited last Annual general meeting of members was held on 31 Jul 2026 as per latest MCA records.
Appointed
Andreas Eugen Busch was appointed as Director.
Appointed
Satyavati Berera was appointed as Director.
Filing
Sun Pharmaceutical Industries Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Appointed
Kirti Wardhaman Ganorkar was appointed as Managing Director.
Ceased
Sudhir Vrundavandas Valia ceased to be Director.
Appointed
Jayashree Satagopan was appointed as CFO.
Ceased
Chinnadharavaram Sundaresan Muralidharan ceased to be CFO.
Appointed
Vidhi Dilip Shanghvi was appointed as Whole-Time Director.
Ceased
Sanjay Khatau Asher ceased to be Director.
Ceased
Sailesh Trambaklal Desai ceased to be Whole-Time Director.
Appointed
Rolf Karl Heinz Hoffmann was appointed as Director.

121 earlier events are in the company report.

News

Sun Pharma: Raises ₹78.2 Billion But Falls Short Of ₹100 Billion Bond Goal.
23 Oct 2026 · Exchange Update
Sun Pharma: Unloxcyt® Gains Category 2A Status In NCCN Guidelines For Patients With Advanced Skin Cancer Not Suitable For Surgery Or Radiation.
20 Oct 2026 · Exchange Update
Sun Pharmaceutical Industries: Board Greenlights ₹10,000 Crore Non-Convertible Debentures And Mr. Gautam Doshi Steps Down As Non-Executive Independent Director Immediately.
12 Oct 2026 · Exchange Update
SUNPHARMA: Rs. 17.18 Crores NSE Block Trade; for ~ 96,878 Shares, at Rs. 1773.00
09 Oct 2026 · Exchange Update
Sun Pharma: Bernstein on Sun Pharma Maintains Outperform, Target Price ₹2,235; Leqselvi now has the clinical credentials to compete with Eli Lilly in alopecia, with market evidence suggesting convenience and label breadth alone do not determine leadership; expects Leqselvi to approach a US$300mn US run-rate by FY29E, with prescription inflection over FY27–29.
08 Oct 2026 · Exchange Update

From our blog

Frequently asked questions

Sun Pharmaceutical Industries is an active public limited company based in Vadodara, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 March 1993 (33+ years old) and is registered under CIN L24230GJ1993PLC019050. Listed on BSE: 524715 and NSE: SUNPHARMA.

Sun Pharmaceutical Industries reported revenue of ₹58,462 Cr for FY 2025-26 (up 11.2% YoY) based on consolidated financials.

Sun Pharmaceutical Industries has 9 current directors:

The latest financial statements of Sun Pharmaceutical Industries on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Sun Pharmaceutical Industries is 24AADCS3124K1ZJ, registered in Gujarat. The company has 41 GST registrations in all, of which 33 are active and 8 are cancelled or inactive. Other active GSTINs include 24AADCS3124K2ZI (Gujarat), 02AADCS3124K1ZP (Himachal Pradesh), 03AADCS3124K2ZM (Punjab).

The CIN (Corporate Identification Number) of Sun Pharmaceutical Industries is L24230GJ1993PLC019050. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Sun Pharmaceutical Industries is a listed company as per MCA records. Its shares are listed on both BSE (code: 524715) and NSE (symbol: SUNPHARMA).

Sun Pharmaceutical Industries has 956 court cases on record: 668 filed by the company and 289 filed against it. 349 are pending. Most are in the high courts.

Sun Pharmaceutical Industries was incorporated on 01 March 1993, making it 33+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Sun Pharmaceutical Industries has 75 deals on record (61 market trades, 6 acquisitions, 4 funding rounds), with disclosed funding of ₹1,610.24 Cr; the latest was in June 2026.

The peers of Sun Pharmaceutical Industries by revenue are Dr.Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Cipla Limited, Zydus Lifesciences Limited, Lupin Limited, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Andreas Eugen Busch was appointed as Director on 12 May 2026. Satyavati Berera was appointed as Director on 08 May 2026. Kirti Wardhaman Ganorkar was appointed as Managing Director on 01 Sep 2025. Sun Pharmaceutical Industries has 42 board changes on record in total.